How Much Does Low-Dose Naltrexone Cost in Delaware in 2026?

What LDN Actually Costs at Delaware Pharmacies

The average cash-pay price for compounded low-dose naltrexone across Delaware retail and compounding pharmacies in 2026 is $50 per month for a 30-day supply of oral capsules. That figure holds whether you fill at a brick-and-mortar 503A compounding pharmacy in Wilmington, Dover, or Newark, or order through a licensed out-of-state compounder that ships to Delaware addresses.

Standard naltrexone (50 mg tablets) carries FDA approval for opioid use disorder and alcohol dependence at its full dose [1]. LDN refers to off-label use at doses between 1.5 mg and 4.5 mg. Because no manufacturer produces naltrexone in these low strengths, every LDN prescription must be filled by a compounding pharmacy. The compounding process itself adds cost, but LDN remains one of the least expensive compounded medications on the market. A pilot crossover trial by Younger et al. (2009, N=10) first demonstrated that 4.5 mg naltrexone nightly reduced fibromyalgia pain severity by 32.5% compared to placebo over 8 weeks [2]. That early evidence base helped fuel patient demand, keeping compounding volumes high and per-unit costs low.

Price can vary by $10 to $20 depending on the pharmacy's compounding overhead and whether you add flavoring or sustained-release formulations. Liquid suspensions for patients who need dose titration below 1.5 mg sometimes cost $55 to $65 per month. Ask your compounder for a standard capsule if cost is the priority.

Delaware Medicaid Coverage for LDN

Delaware Medicaid covers low-dose naltrexone with prior authorization. The PA requirement exists because LDN prescriptions are off-label, and Medicaid formularies across all 50 states classify off-label compounded medications as non-preferred.

To obtain PA approval, your prescribing clinician must submit documentation of the specific diagnosis (fibromyalgia, Crohn's disease, multiple sclerosis, or another inflammatory or autoimmune condition), evidence that first-line therapies have been tried or are contraindicated, and a letter of medical necessity citing peer-reviewed evidence. A 2013 follow-up trial by Younger et al. (N=31) showed that LDN 4.5 mg produced a 28.8% reduction in daily pain scores among fibromyalgia patients, significantly exceeding the placebo response [3]. Citing this trial and subsequent replications strengthens a PA request.

Processing time for Delaware Medicaid PA decisions typically runs 24 to 72 hours for standard requests and 24 hours for urgent requests. If denied, your prescriber can file a fair hearing appeal through the Delaware Division of Medicaid and Medical Assistance (DMMA). The DMMA administers benefits through managed care organizations including Highmark Health Options and AmeriHealth Caritas Delaware, and PA requirements may differ slightly between MCOs.

Commercial Insurance and LDN in Delaware

Most commercial health plans in Delaware do not cover compounded LDN on their standard formularies. This applies to plans from Highmark Blue Cross Blue Shield of Delaware, Aetna, Cigna, and UnitedHealthcare, all of which operate in the state's individual and employer-sponsored markets.

The reason is straightforward. Compounded medications sit outside the FDA-approved drug supply chain, so pharmacy benefit managers (PBMs) like Express Scripts and CVS Caremark typically exclude them from formulary tiers. Your plan may cover FDA-approved naltrexone 50 mg tablets (generic, often $15 to $30 per month with insurance), but that dose serves an entirely different clinical purpose.

A prior authorization request for off-label compounded LDN can still succeed with commercial insurers. The process mirrors the Medicaid pathway: diagnosis documentation, evidence of failed alternatives, and a letter of medical necessity. Success rates vary. Some patients report approval after a single appeal; others exhaust the appeals process and default to cash pay. At $50 per month, many Delaware patients find cash pay more practical than the administrative burden of repeated PA submissions. The Endocrine Society's 2023 clinical practice guidelines have noted the growing body of evidence for naltrexone's immunomodulatory effects at low doses, though formal guideline endorsement for specific off-label indications remains limited [4].

How 503A Compounding Works in Delaware

LDN is legally compounded and dispensed in Delaware through 503A-registered pharmacies. A 503A pharmacy compounds medications pursuant to individual patient prescriptions, as authorized under Section 503A of the Federal Food, Drug, and Cosmetic Act [5].

Delaware's Board of Pharmacy licenses and inspects compounding pharmacies operating within state borders. Out-of-state 503A pharmacies may also ship compounded LDN to Delaware patients provided they hold a non-resident pharmacy license from the Delaware Board. This expands access significantly. Patients in Sussex County or Kent County who lack a local compounding pharmacy can order from licensed compounders in neighboring states like Pennsylvania, Maryland, or New Jersey.

The distinction between 503A and 503B pharmacies matters for pricing. 503A pharmacies compound per-prescription and tend to price LDN at $40 to $60 per month. 503B outsourcing facilities compound in bulk without individual prescriptions but primarily supply healthcare facilities rather than individual patients. For most Delaware residents filling a personal LDN prescription, a 503A pharmacy is the relevant channel.

To verify that a pharmacy holds proper Delaware licensure, search the Delaware Division of Professional Regulation's license verification portal or call the Board of Pharmacy directly at (302) 744-4500.

Telehealth Access to LDN in Delaware

Delaware permits telehealth prescribing of low-dose naltrexone. Clinicians licensed in Delaware can evaluate patients via synchronous video or audio visits and issue prescriptions for compounded LDN that are valid at any licensed pharmacy.

Several national telehealth platforms now offer LDN consultations for Delaware residents. Consultation fees typically range from $75 to $150 for an initial visit, with follow-ups at $50 to $100. Some platforms bundle the consultation fee with the medication cost into a monthly subscription ($99 to $149 per month including the compounded LDN supply).

Telehealth is particularly relevant for Delaware's rural communities. Sussex County, which covers roughly 40% of the state's land area, has fewer specialty providers per capita than New Castle County. A patient in Georgetown or Rehoboth Beach who would otherwise drive 60 to 90 minutes to reach an integrative medicine practice in Wilmington can complete the entire consultation and prescription process remotely. The prescription is then mailed from a licensed 503A compounder directly to the patient's address.

The Ryan Haight Online Pharmacy Consumer Protection Act requires a valid prescriber-patient relationship before controlled substance prescriptions can be issued via telehealth [6]. Naltrexone is not a controlled substance under the DEA's scheduling, so this restriction does not apply. Any Delaware-licensed prescriber (MD, DO, NP, or PA) can prescribe LDN via telehealth without an in-person visit prerequisite.

Finding the Cheapest LDN in Delaware

The lowest-cost route to LDN in Delaware is a direct cash-pay purchase from a 503A compounding pharmacy, which runs approximately $50 per month for standard 4.5 mg capsules.

Here are four strategies to reduce that cost further:

Compare compounding pharmacies. Prices at Delaware-based compounders can vary by $10 to $20 per month. Phone quotes from two or three pharmacies often reveal a lower option. Out-of-state compounders with Delaware non-resident licenses sometimes price lower due to higher volume.

Use a pharmacy discount card. GoodRx, RxSaver, and similar platforms occasionally list compounded LDN pricing, though coverage of compounded medications is less consistent than for FDA-approved generics. Always confirm the discount applies to the compounded product before assuming savings.

Ask about multi-month supplies. Some compounding pharmacies offer a 90-day supply at a reduced per-month rate. A 90-day supply at $130 brings the monthly cost down to roughly $43.

Consider telehealth subscription bundles. If you are paying for both a consultation and the medication, a bundled telehealth plan at $99 to $130 per month (visit plus medication plus shipping) may be comparable to paying a $100+ office visit fee plus $50 for the medication separately. Run the math based on your visit frequency.

Generic naltrexone 50 mg tablets cost as little as $10 to $25 per month at retail pharmacies, but splitting or dissolving a 50 mg tablet to achieve a 4.5 mg dose is imprecise and not recommended. Compounding ensures dose accuracy, capsule uniformity, and appropriate excipient selection. The FDA has specifically warned against patients modifying commercially available dosage forms to create unapproved doses [7].

What the Evidence Says About LDN

Low-dose naltrexone's proposed mechanism involves transient blockade of opioid receptors, which may upregulate endogenous opioid production and modulate toll-like receptor 4 (TLR4) signaling on microglia and macrophages [8]. This immunomodulatory hypothesis explains why researchers have investigated LDN across a range of inflammatory and autoimmune conditions rather than solely for pain.

The evidence base, while growing, consists largely of small trials and observational studies. The Younger et al. 2009 pilot (N=10) was a single-blind crossover design with significant limitations in sample size and blinding [2]. The 2013 follow-up (N=31) was double-blind, placebo-controlled, and showed a 28.8% reduction in fibromyalgia symptoms from baseline, with 57% of participants meeting responder criteria (defined as a 30% or greater reduction in symptoms) [3].

For Crohn's disease, a randomized controlled trial by Smith et al. (2011, N=40) found that 4.5 mg naltrexone nightly produced endoscopic remission in 25% of patients versus 0% on placebo, with clinical response rates of 88% versus 40% (P<0.01) [9]. A systematic review published in 2022 identified 89 published studies on LDN across multiple conditions, noting consistent signals of benefit but calling for larger, multi-center RCTs before formal guideline adoption [10].

Dr. Jarred Younger, the neuroscientist at the University of Alabama at Birmingham who led the original fibromyalgia trials, has stated: "LDN appears to work through an anti-inflammatory mechanism rather than a traditional analgesic pathway, which is why the effective dose is a fraction of the standard 50 mg" [2].

The American Academy of Family Physicians (AAFP) has not issued a formal recommendation for or against LDN, noting insufficient evidence for a guideline-level position [11]. Prescribers who recommend LDN in Delaware are doing so on an off-label, evidence-informed basis.

Dose, Administration, and What to Expect

Standard LDN dosing starts at 1.5 mg nightly and titrates upward to 4.5 mg over two to four weeks. The titration schedule helps minimize early side effects, which most commonly include vivid dreams, mild headache, and transient nausea during the first one to two weeks of therapy.

Take LDN at bedtime. The transient opioid receptor blockade that triggers the compensatory upregulation occurs during sleep, and bedtime dosing aligns the pharmacologic effect with the body's natural endorphin cycle. Most patients take LDN as a single oral capsule with water, with or without food.

Onset of benefit varies by condition. Fibromyalgia patients in the Younger trials reported measurable symptom improvement within 8 weeks [3]. Crohn's disease patients in the Smith trial showed endoscopic changes at 12 weeks [9]. Prescribers generally recommend a minimum 8-to-12-week trial before assessing response.

LDN is contraindicated in patients currently taking opioid medications (including opioid-containing cough suppressants) because even low-dose naltrexone can precipitate opioid withdrawal. Patients must be opioid-free for a minimum of 7 to 14 days before starting LDN. Discuss all current medications with your prescriber before beginning therapy.

Delaware-Specific Regulatory Considerations

Delaware does not impose state-level restrictions on LDN prescribing beyond standard prescriptive authority requirements. Any Delaware-licensed prescriber with authority to prescribe legend drugs (physicians, nurse practitioners with full practice authority, and physician assistants under a collaborative agreement) can write an LDN prescription.

Delaware granted full practice authority to nurse practitioners in 2015, meaning NPs can independently prescribe LDN without physician oversight. This expands access in primary care and integrative medicine settings where NPs are often the first point of contact.

The Delaware Board of Pharmacy follows USP <795> standards for non-sterile compounding, which govern how 503A pharmacies prepare LDN capsules. These standards address potency, beyond-use dating, and quality assurance testing. Patients can request a certificate of analysis (COA) from their compounding pharmacy to verify that their LDN capsules meet potency specifications.

A 2024 FDA guidance update reaffirmed that naltrexone is not on the FDA's "difficult to compound" list and is not a bulk drug substance requiring FDA evaluation for 503A use, keeping the compounding pathway straightforward for pharmacies [5].